Developability and Characterization
The Developability & Characterization pipeline brings together three cutting-edge programs exploring advancements in predicting, analyzing, and optimizing critical quality attributes across diverse biotherapeutic modalities. Attendees will gain insights into leveraging AI and ML tools for modeling developability parameters, applying analytical techniques to assess aggregation, stability, and immunogenicity, and tailoring characterization approaches to novel biologic drug formats. Industry experts will share experiences and discuss pressing issues through case studies, unpublished data, interactive panel discussions, and keynote presentations. The symposia and tracks showcase characterization techniques, comparing their applicability across drug classes, encouraging attendees to consider novel approaches in their programs.
January 13
January 14-15
January 15-16
KEYNOTE PRESENTATION:
Overview of the History and Progress of Therapeutic Neurotoxin Development
Sathya Venkataramani, PhD, Director, Protein Science, Abbvie
If you are working in the following areas join the PepTalk community:
Analytical Sciences
Analytical Chemistry
Analytical Development
Analytical Development
Analytical Operations
Analytical Science & Technology
Applied Spectroscopy
Assay Development
Biologics Technical Development
Bioprocess Development
Bioprocessing
Cell Therapy R&D
CMC
Early CMC & Analytical
Gene Therapy R&D
Manufacturing Science & Technology (MSAT)
Mass Spectrometry
Protein Analytical Chemistry
Protein Biochemistry
Quality Control
R&D
Technical Development